Array BioPharma Stock Price, News & Analysis (NASDAQ:ARRY)

$11.48 0.15 (1.32 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$11.33
Today's Range$11.35 - $11.62
52-Week Range$6.73 - $13.40
Volume1.25 million shs
Average Volume3.89 million shs
Market Capitalization$2.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.93

About Array BioPharma (NASDAQ:ARRY)

Array BioPharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARRY
CUSIP04269X10
Phone303-381-6600

Debt

Debt-to-Equity Ratio0.54%
Current Ratio5.43%
Quick Ratio5.43%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$150.85 million
Price / Sales14.99
Cash FlowN/A
Price / CashN/A
Book Value$1.15 per share
Price / Book9.98

Profitability

Trailing EPS($0.74)
Net Income$-116,810,000.00
Net Margins-89.30%
Return on Equity-158.70%
Return on Assets-38.54%

Miscellaneous

Employees209
Outstanding Shares197,030,000

Frequently Asked Questions for Array BioPharma (NASDAQ:ARRY)

What is Array BioPharma's stock symbol?

Array BioPharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array BioPharma's earnings last quarter?

Array BioPharma Inc. (NASDAQ:ARRY) issued its quarterly earnings data on Tuesday, October, 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.22). The biopharmaceutical company earned $29.75 million during the quarter, compared to the consensus estimate of $33.74 million. Array BioPharma had a negative net margin of 89.30% and a negative return on equity of 158.70%. The firm's revenue was down 24.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. View Array BioPharma's Earnings History.

When will Array BioPharma make its next earnings announcement?

Array BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for Array BioPharma.

Where is Array BioPharma's stock going? Where will Array BioPharma's stock price be in 2017?

8 brokers have issued 1 year target prices for Array BioPharma's shares. Their forecasts range from $9.00 to $18.00. On average, they anticipate Array BioPharma's stock price to reach $14.13 in the next year. View Analyst Ratings for Array BioPharma.

What are Wall Street analysts saying about Array BioPharma stock?

Here are some recent quotes from research analysts about Array BioPharma stock:

  • 1. Cantor Fitzgerald analysts commented, "ARRY’s e-poster presentation of the safety lead in for the Phase III BEACON CRC study suggests that binimetinib/encorafenib could expand its market potential to colorectal cancer, which the shares do not currently reflect, in our view." (9/8/2017)
  • 2. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (8/11/2017)
  • 3. Cowen Inc analysts commented, "We see ARRY's decision to withdraw the NRAS NDA as prudent given the known modest efficacy benefit. The NRAS-mutant melanoma opportunity represented a modest 6% of our base model DCF, thus we lower our PT modestly from $15 to $14. We view recent share weakness and the passing of this 'risk' event as an especially attractive opportunity to firmly reiterate our Outperform rating on ARRY shares." (3/20/2017)

Who are some of Array BioPharma's key competitors?

Who are Array BioPharma's key executives?

Array BioPharma's management team includes the folowing people:

  • Kyle A. Lefkoff, Independent Chairman of the Board (Age 56)
  • Ron R. Squarer, Chief Executive Officer, Director (Age 50)
  • Jason Haddock, Chief Financial Officer (Age 47)
  • Andrew R. Robbins, Chief Operating Officer (Age 41)
  • Nicholas A. Saccomano Ph.D., Chief Scientific Officer (Age 58)
  • Curtis Gale Oltmans, General Counsel (Age 54)
  • Victor Sandor, Chief Medical Officer (Age 51)
  • Shalini Sharp, Director (Age 42)
  • Charles M. Baum M.D., Ph.D., Independent Director (Age 59)
  • Gwendolyn A. Fyfe M.D., Independent Director (Age 65)

Who owns Array BioPharma stock?

Array BioPharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include POINT72 ASSET MANAGEMENT, L.P. Total Shares: 9,194,118 (5.40%), Point72 Asset Management L.P. (4.57%), Pinnacle Associates Ltd. (1.51%), Bank of New York Mellon Corp (0.49%), Schwab Charles Investment Management Inc. (0.40%) and Candriam Luxembourg S.C.A. (0.38%). Company insiders that own Array BioPharma stock include Charles M Baum, Kyle Lefkoff and Redmile Group, Llc. View Institutional Ownership Trends for Array BioPharma.

Who sold Array BioPharma stock? Who is selling Array BioPharma stock?

Array BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Cambiar Investors LLC, Sphera Funds Management LTD., OxFORD Asset Management LLP, Canada Pension Plan Investment Board, First Trust Advisors LP, Pinnacle Associates Ltd., Chicago Equity Partners LLC and Cubist Systematic Strategies LLC. Company insiders that have sold Array BioPharma company stock in the last year include Charles M Baum and Kyle Lefkoff. View Insider Buying and Selling for Array BioPharma.

Who bought Array BioPharma stock? Who is buying Array BioPharma stock?

Array BioPharma's stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Pictet Asset Management Ltd., Candriam Luxembourg S.C.A., Nicholas Investment Partners LP, Nationwide Fund Advisors, EAM Investors LLC, Bank of New York Mellon Corp and Ameriprise Financial Inc.. View Insider Buying and Selling for Array BioPharma.

How do I buy Array BioPharma stock?

Shares of Array BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array BioPharma's stock price today?

One share of Array BioPharma stock can currently be purchased for approximately $11.48.

How big of a company is Array BioPharma?

Array BioPharma has a market capitalization of $2.23 billion and generates $150.85 million in revenue each year. The biopharmaceutical company earns $-116,810,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Array BioPharma employs 209 workers across the globe.

How can I contact Array BioPharma?

Array BioPharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]


MarketBeat Community Rating for Array BioPharma (ARRY)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  415
MarketBeat's community ratings are surveys of what our community members think about Array BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Array BioPharma (NASDAQ:ARRY)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.582.582.582.89
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.65$12.65$11.21$11.21
Price Target Upside: 30.65% upside12.08% upside21.57% upside56.11% upside

Consensus Price Target History for Array BioPharma (NASDAQ:ARRY)

Price Target History for Array BioPharma (NASDAQ:ARRY)

Analysts' Ratings History for Array BioPharma (NASDAQ:ARRY)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/1/2017SunTrust Banks, Inc.Reiterated RatingBuy$16.00N/AView Rating Details
11/1/2017Stifel NicolausReiterated RatingBuyN/AView Rating Details
10/31/2017Cantor FitzgeraldSet Price TargetBuy$15.00N/AView Rating Details
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$14.00 -> $18.00LowView Rating Details
9/12/2017Jefferies Group LLCReiterated RatingBuy$9.00MediumView Rating Details
9/11/2017Cowen IncReiterated RatingOutperform$14.00 -> $15.00HighView Rating Details
9/11/2017J P Morgan Chase & CoReiterated RatingBuy$14.00HighView Rating Details
1/30/2017Leerink SwannDowngradeOutperform -> Market Perform$11.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Array BioPharma (NASDAQ:ARRY)

Earnings by Quarter for Array BioPharma (NASDAQ:ARRY)

Earnings History by Quarter for Array BioPharma (NASDAQ ARRY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018N/AView Earnings Details
10/31/2017Q1 2018($0.22)($0.22)$33.74 million$29.75 millionViewN/AView Earnings Details
8/9/2017Q4 2017($0.21)($0.17)$28.64 million$33.80 millionViewListenView Earnings Details
5/10/2017Q3 2017($0.16)($0.21)$38.28 million$33.28 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.20)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Array BioPharma (NASDAQ:ARRY)
2017 EPS Consensus Estimate: ($0.94)
2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.21)($0.22)
Q2 20173($0.27)($0.20)($0.22)
Q3 20173($0.31)($0.22)($0.25)
Q4 20173($0.29)($0.21)($0.25)
Q1 20182($0.31)($0.19)($0.25)
Q2 20182($0.32)($0.18)($0.25)
Q3 20182($0.36)($0.18)($0.27)
Q4 20182($0.26)($0.21)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Array BioPharma (NASDAQ:ARRY)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Array BioPharma (NASDAQ ARRY)

Insider Ownership Percentage: 3.18%
Institutional Ownership Percentage: 88.15%
Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)

Insider Trades by Quarter for Array BioPharma (NASDAQ ARRY)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/29/2017Kyle LefkoffDirectorSell38,865$12.31$478,428.15View SEC Filing  
3/28/2017Charles M BaumDirectorSell25,000$9.27$231,750.00View SEC Filing  
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Array BioPharma (NASDAQ ARRY)

Source:
DateHeadline
ARRY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving ... - Business Wire (press release)ARRY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving ... - Business Wire (press release)
www.businesswire.com - November 22 at 4:39 PM
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Array Biopharma, Inc. - GlobeNewswire (press release)Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Array Biopharma, Inc. - GlobeNewswire (press release)
globenewswire.com - November 22 at 4:39 PM
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Array Biopharma, Inc.Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Array Biopharma, Inc.
finance.yahoo.com - November 22 at 4:39 PM
Is the Options Market Predicting a Spike in Array BioPharma (ARRY) Stock?Is the Options Market Predicting a Spike in Array BioPharma (ARRY) Stock?
finance.yahoo.com - November 22 at 2:41 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 – ARRYSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint on Behalf of Array Biopharma Inc. Shareholders and Lead Plaintiff Deadline of January 22, 2018 – ARRY
finance.yahoo.com - November 22 at 2:41 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Array Biopharma, Inc. - ARRYSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Array Biopharma, Inc. - ARRY
finance.yahoo.com - November 21 at 9:40 PM
ARRAY BIOPHARMA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Array Biopharma, Inc. To Contact The FirmARRAY BIOPHARMA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Array Biopharma, Inc. To Contact The Firm
finance.yahoo.com - November 21 at 9:40 PM
Array BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : November 20, 2017Array BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : November 20, 2017
finance.yahoo.com - November 20 at 3:19 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Array BioPharma Inc.INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Array BioPharma Inc.
finance.yahoo.com - November 20 at 3:18 PM
Array BioPharma Announces Private Exchange of $107 Million of its 3.00% Convertible Senior Notes due 2020 for its ... - PR Newswire (press release)Array BioPharma Announces Private Exchange of $107 Million of its 3.00% Convertible Senior Notes due 2020 for its ... - PR Newswire (press release)
www.prnewswire.com - November 18 at 4:03 PM
Array BioPharma Sees Unusually High Options Volume (ARRY)Array BioPharma Sees Unusually High Options Volume (ARRY)
www.americanbankingnews.com - November 17 at 1:26 AM
Array BioPharma Announces Private Exchange of $107 Million of its 3.00% Convertible Senior Notes due 2020 for its 2.625% Convertible Senior Notes due 2024 and Shares of its Common StockArray BioPharma Announces Private Exchange of $107 Million of its 3.00% Convertible Senior Notes due 2020 for its 2.625% Convertible Senior Notes due 2024 and Shares of its Common Stock
finance.yahoo.com - November 16 at 9:22 PM
ETFs with exposure to Array BioPharma, Inc. : November 16, 2017ETFs with exposure to Array BioPharma, Inc. : November 16, 2017
finance.yahoo.com - November 16 at 11:28 AM
Array BioPharma Inc. (ARRY) Expected to Post Earnings of -$0.23 Per ShareArray BioPharma Inc. (ARRY) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - November 15 at 5:22 PM
Array BioPharma Inc. (ARRY) Receives Consensus Rating of "Buy" from AnalystsArray BioPharma Inc. (ARRY) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 13 at 8:14 AM
Array BioPharma To Present At The 2017 Stifel Healthcare ConferenceArray BioPharma To Present At The 2017 Stifel Healthcare Conference
finance.yahoo.com - November 8 at 6:16 PM
Array BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : November 6, 2017Array BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : November 6, 2017
finance.yahoo.com - November 6 at 5:02 PM
ETFs with exposure to Array BioPharma, Inc. : November 6, 2017ETFs with exposure to Array BioPharma, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 5:02 PM
FY2018 Earnings Estimate for Array BioPharma Inc. (ARRY) Issued By Cantor FitzgeraldFY2018 Earnings Estimate for Array BioPharma Inc. (ARRY) Issued By Cantor Fitzgerald
www.americanbankingnews.com - November 6 at 1:36 PM
Array BioPharma, Inc. :ARRY-US: Earnings Analysis: Q1, 2018 By the Numbers : November 3, 2017Array BioPharma, Inc. :ARRY-US: Earnings Analysis: Q1, 2018 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 4:25 PM
SunTrust Banks Weighs in on Array BioPharma Inc.s FY2020 Earnings (ARRY)SunTrust Banks Weighs in on Array BioPharma Inc.'s FY2020 Earnings (ARRY)
www.americanbankingnews.com - November 2 at 5:34 PM
SunTrust Banks, Inc. Reaffirms Buy Rating for Array BioPharma Inc. (ARRY)SunTrust Banks, Inc. Reaffirms Buy Rating for Array BioPharma Inc. (ARRY)
www.americanbankingnews.com - November 1 at 8:28 PM
Todays Research Reports on Stocks to Watch: Incyte Corporation and Array BioPharmaToday's Research Reports on Stocks to Watch: Incyte Corporation and Array BioPharma
finance.yahoo.com - November 1 at 4:36 PM
Edited Transcript of ARRY earnings conference call or presentation 31-Oct-17 1:00pm GMTEdited Transcript of ARRY earnings conference call or presentation 31-Oct-17 1:00pm GMT
finance.yahoo.com - November 1 at 1:26 AM
Cantor Fitzgerald Reiterates $15.00 Price Target for Array BioPharma Inc. (ARRY)Cantor Fitzgerald Reiterates $15.00 Price Target for Array BioPharma Inc. (ARRY)
www.americanbankingnews.com - October 31 at 7:18 PM
EARNINGS SUMMARY: Details of Array BioPharma Inc. Q1 Earnings ReportEARNINGS SUMMARY: Details of Array BioPharma Inc. Q1 Earnings Report
www.rttnews.com - October 31 at 3:17 PM
Array BioPharma Inc. to Host Earnings CallArray BioPharma Inc. to Host Earnings Call
finance.yahoo.com - October 31 at 3:17 PM
Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2018Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2018
finance.yahoo.com - October 31 at 3:17 PM
Array BioPharma reports 1Q lossArray BioPharma reports 1Q loss
finance.yahoo.com - October 31 at 3:16 PM
Have Investors Already Priced In Array BioPharma Inc’s (ARRY) Growth?Have Investors Already Priced In Array BioPharma Inc’s (ARRY) Growth?
finance.yahoo.com - October 31 at 3:16 PM
Array BioPharma Inc. (ARRY) Posts Quarterly  Earnings Results, Hits EstimatesArray BioPharma Inc. (ARRY) Posts Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - October 31 at 12:30 PM
Zacks: Analysts Expect Array BioPharma Inc. (ARRY) Will Post Quarterly Sales of $22.34 MillionZacks: Analysts Expect Array BioPharma Inc. (ARRY) Will Post Quarterly Sales of $22.34 Million
www.americanbankingnews.com - October 28 at 9:53 AM
Array BioPharma, Inc. – Value Analysis (NASDAQ:ARRY) : October 25, 2017Array BioPharma, Inc. – Value Analysis (NASDAQ:ARRY) : October 25, 2017
finance.yahoo.com - October 25 at 5:10 PM
Implied PTH Analyst Target Price: $76Implied PTH Analyst Target Price: $76
www.nasdaq.com - October 24 at 5:51 PM
Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : October 24, 2017Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : October 24, 2017
finance.yahoo.com - October 24 at 5:51 PM
Array Biopharma To Report Financial Results For The First Quarter Of Fiscal 2018 On October 31, 2017Array Biopharma To Report Financial Results For The First Quarter Of Fiscal 2018 On October 31, 2017
finance.yahoo.com - October 24 at 5:51 PM
Array BioPharma Inc. (ARRY) Scheduled to Post Quarterly Earnings on MondayArray BioPharma Inc. (ARRY) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 10:54 AM
Array BioPharma Inc. (ARRY) Receives Average Recommendation of "Buy" from AnalystsArray BioPharma Inc. (ARRY) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 19 at 9:07 AM
After Hours Most Active for Oct 16, 2017 : NFLX, PE, F, MAR, ISBC, LB, GE, SYF, LUV, CMCSA, QQQ, ARRY - NasdaqAfter Hours Most Active for Oct 16, 2017 : NFLX, PE, F, MAR, ISBC, LB, GE, SYF, LUV, CMCSA, QQQ, ARRY - Nasdaq
www.nasdaq.com - October 16 at 9:54 PM
Short Interest in Array BioPharma Inc. (ARRY) Decreases By 18.6%Short Interest in Array BioPharma Inc. (ARRY) Decreases By 18.6%
www.americanbankingnews.com - October 13 at 1:32 AM
ETFs with exposure to Array BioPharma, Inc. : October 9, 2017ETFs with exposure to Array BioPharma, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 5:00 PM
Zacks: Analysts Anticipate Array BioPharma Inc. (ARRY) to Post -$0.22 Earnings Per ShareZacks: Analysts Anticipate Array BioPharma Inc. (ARRY) to Post -$0.22 Earnings Per Share
www.americanbankingnews.com - October 7 at 8:38 AM
Head-To-Head Contrast: Array BioPharma (ARRY) & Its CompetitorsHead-To-Head Contrast: Array BioPharma (ARRY) & Its Competitors
www.americanbankingnews.com - October 2 at 4:20 PM
Insider Selling: Array BioPharma Inc. (ARRY) Director Sells 38,865 Shares of StockInsider Selling: Array BioPharma Inc. (ARRY) Director Sells 38,865 Shares of Stock
www.americanbankingnews.com - September 29 at 7:39 PM
Array BioPharma Inc. (ARRY) Short Interest Up 20.6% in SeptemberArray BioPharma Inc. (ARRY) Short Interest Up 20.6% in September
www.americanbankingnews.com - September 28 at 2:20 AM
Array BioPharma (ARRY) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowArray BioPharma (ARRY) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 7:55 PM
Cantor Fitzgerald Reiterates Buy Rating for Array BioPharma Inc. (ARRY)Cantor Fitzgerald Reiterates Buy Rating for Array BioPharma Inc. (ARRY)
www.americanbankingnews.com - September 27 at 6:10 PM
Array BioPharma Inc. (ARRY) Given Average Rating of "Buy" by BrokeragesArray BioPharma Inc. (ARRY) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 24 at 9:00 AM
Array BioPharma Inc. (ARRY) Rating Reiterated by Piper Jaffray CompaniesArray BioPharma Inc. (ARRY) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - September 20 at 10:52 PM
$22.34 Million in Sales Expected for Array BioPharma Inc. (ARRY) This Quarter$22.34 Million in Sales Expected for Array BioPharma Inc. (ARRY) This Quarter
www.americanbankingnews.com - September 20 at 9:24 AM

Social Media

Financials

Chart

Array BioPharma (NASDAQ ARRY) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.